List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9106330/publications.pdf Version: 2024-02-01



Ін-Гли Тлис

#	Article	IF	CITATIONS
1	Hepatitis B surface antigen positivity is associated with progression of disease within 24Âmonths in follicular lymphoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1211-1222.	1.2	4
2	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. Bone Marrow Transplantation, 2022, 57, 95-105.	1.3	8
3	NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. International Journal of Hematology, 2022, , 1.	0.7	3
4	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. Journal of the Formosan Medical Association, 2021, 120, 293-302.	0.8	4
5	Busulfanâ€containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. Cancer Reports, 2021, , e1488.	0.6	2
6	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. Journal of the Formosan Medical Association, 2021, 121, 643-643.	0.8	1
7	Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008–2013. Journal of Microbiology, Immunology and Infection, 2020, 53, 106-114.	1.5	24
8	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden. Blood Cancer Journal, 2020, 10, 99.	2.8	5
9	Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. International Journal of Hematology, 2020, 112, 385-394.	0.7	2
10	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Annals of Hematology, 2020, 99, 501-511.	0.8	52
11	Next-Generation Sequencing Minimal Residual Disease of Mantle Cell Lymphoma in Autologous Stem Cell Grafts and Its Implication on Tumor Recurrence. Blood, 2020, 136, 22-23.	0.6	0
12	NOVEL-1st: A Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan. Blood, 2020, 136, 2-3.	0.6	0
13	A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤0 kg. Bone Marrow Transplantation, 2019, 54, 258-264.	1.3	1
14	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine, 2019, 40, 240-250.	2.7	23
15	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2019, 19, 617.	1.1	43
16	Clonal sequence tracking reveals TET2-mutated extranodal NK/T-cell lymphoma disseminated independent of Epstein Barr virus. Haematologica, 2019, 104, e489-e492.	1.7	1
17	Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005–2015. Bone Marrow Transplantation, 2019, 54, 1973-1986.	1.3	29
18	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 2019, 133, 1140-1151.	0.6	96

#	Article	IF	CITATIONS
19	The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia. Blood, 2019, 134, 2705-2705.	0.6	Ο
20	Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. Therapeutic Advances in Hematology, 2018, 9, 65-78.	1.1	9
21	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2018, 101, 28-37.	1.1	8
22	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer Journal, 2018, 8, 39.	2.8	68
23	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poorâ€risk factor in <i>de novo</i> acute myeloid leukemia patients. European Journal of Haematology, 2018, 101, 86-94.	1.1	31
24	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	1.8	36
25	2016 guideline strategies for the use ofÂantifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. Journal of Microbiology, Immunology and Infection, 2018, 51, 287-301.	1.5	13
26	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine, 2018, 37, 91-100.	2.7	54
27	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 87.	2.8	34
28	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . Haematologica, 2018, 103, e510-e513.	1.7	29
29	Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 2310-2315.	2.0	4
30	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterology, 2018, 18, 6.	0.8	20
31	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	1.4	20
32	Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3-ITD Patients. Blood, 2018, 132, 3977-3977.	0.6	1
33	Discrepant Mutational Composition between Myeloid Sarcoma and Bone Marrow Leukemia Revealed through Targeted Next Generation Sequencing. Blood, 2018, 132, 1395-1395.	0.6	1
34	Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. International Journal of Antimicrobial Agents, 2017, 49, 272-281.	1.1	41
35	Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase. Biology of Blood and Marrow Transplantation, 2017, 23, 1367-1373.	2.0	3
36	Reactive Follicular Hyperplasia With Perifollicular Granulomas and Increased IgG4-Positive Plasma Cells. International Journal of Surgical Pathology, 2017, 25, 698-699.	0.4	0

#	Article	IF	CITATIONS
37	Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. Journal of Radiation Research, 2017, 58, 114-122.	0.8	12
38	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 663.	2.8	39
39	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. Oncotarget, 2017, 8, 81329-81342.	0.8	6
40	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. Scientific Reports, 2016, 6, 36730.	1.6	18
41	Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. Annals of Hematology, 2016, 95, 593-601.	0.8	45
42	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget, 2016, 7, 63177-63188.	0.8	21
43	Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget, 2016, 7, 62490-62502.	0.8	30
44	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. Oncotarget, 2016, 7, 9084-9101.	0.8	77
45	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 49-49.	0.6	0
46	Clinical Features and Morbidities of Hb H Disease in Taiwan. Blood, 2016, 128, 4836-4836.	0.6	1
47	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0119831.	1.1	6
48	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0126037.	1.1	21
49	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. PLoS ONE, 2015, 10, e0137552.	1.1	7
50	Clinical characteristics and treatment outcomes of patients with candidaemia due to <i>Candida parapsilosis sensu lato</i> species at a medical centre in Taiwan, 2000–12. Journal of Antimicrobial Chemotherapy, 2015, 70, 1531-1538.	1.3	21
51	GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. Annals of Hematology, 2015, 94, 211-221.	0.8	23
52	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS ONE, 2015, 10, e0128410.	1.1	50
53	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer, 2015, 15, 344.	1.1	48
54	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 4956-4956.	0.6	0

JIH-LUH TANG

#	Article	IF	CITATIONS
55	Demographics and Long-Term Outcome of Incident Immune Thrombocytopenic Purpura: A Twelve-Years Nationwide Population-Based Study in Taiwan. Blood, 2015, 126, 3259-3259.	0.6	1
56	IPSSâ€R in 555 <scp>Taiwanese</scp> patients with primary MDS: Integration of monosomal karyotype can better riskâ€stratify the patients. American Journal of Hematology, 2014, 89, E142-9.	2.0	16
57	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i> , <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. American Journal of Hematology, 2014, 89, 137-144.	2.0	76
58	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2014, 89, 181-186.	2.0	56
59	Microsatellite Instability Confounds Engraftment Analysis of Hematopoietic Stem-cell Transplantation. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 416-420.	0.6	13
60	Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Annals of Hematology, 2014, 93, 1371-1380.	0.8	54
61	Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leukemia Research, 2014, 38, 1278-1284.	0.4	22
62	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. American Journal of Hematology, 2014, 89, E109-15.	2.0	34
63	Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. International Journal of Hematology, 2014, 100, 7-15.	0.7	7
64	The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. Haematologica, 2014, 99, 1799-1807.	1.7	13
65	Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. BMC Cancer, 2013, 13, 107.	1.1	11
66	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East. Annals of Hematology, 2013, 92, 799-806.	0.8	14
67	Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. Journal of Antimicrobial Chemotherapy, 2013, 68, 2632-2635.	1.3	24
68	Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2013, 88, E277-82.	2.0	56
69	Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood, 2013, 121, 3172-3180.	0.6	58
70	Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiation Oncology, 2013, 8, 245.	1.2	26
71	Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia. PLoS ONE, 2013, 8, e60624.	1.1	48
72	The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 2012, 120, 3106-3111.	0.6	127

#	Article	IF	CITATIONS
73	Impact of Donor Characteristics and HLA Matching on Survival of Chinese Patients with Hematologic Malignancies Undergoing Unrelated Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1939-1944.	2.0	7
74	Intracranial hemorrhage in adult patients with hematological malignancies. BMC Medicine, 2012, 10, 97.	2.3	58
75	Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010. International Journal of Antimicrobial Agents, 2012, 40, 533-538.	1.1	30
76	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 2012, 119, 559-568.	0.6	211
77	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 2011, 118, 3803-3810.	0.6	272
78	Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan. BMC Infectious Diseases, 2011, 11, 250.	1.3	98
79	Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infectious Diseases, 2011, 11, 324.	1.3	38
80	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica, 2010, 95, 1420-1424.	1.7	17
81	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115, 2749-2754.	0.6	193
82	WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood, 2010, 115, 5222-5231.	0.6	156
83	Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era. Leukemia Research, 2010, 34, 1459-1471.	0.4	36
84	Minor histocompatibility antigen HA-1 and HA-2 polymorphisms in Taiwan: frequency and application in hematopoietic stem cell transplantation. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1287-93.	1.4	4
85	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 2010, 116, 4086-4094.	0.6	187
86	Functional polymorphism of CTLA-4 and ICOS genes in allogeneic hematopoietic stem cell transplantation. Clinica Chimica Acta, 2009, 403, 229-233.	0.5	33
87	HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia. Journal of the Formosan Medical Association, 2009, 108, 423-427.	0.8	2
88	Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood, 2009, 113, 3161-3167.	0.6	75
89	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood, 2009, 114, 5352-5361.	0.6	318
90	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations Blood, 2009, 114, 1564-1564.	0.6	3

#	Article	IF	CITATIONS
91	Syngeneic Blood and Marrow Transplantation: A Report of 94 Cases From Chinese Society of Blood and Marrow Transplantation (CSBMT) Blood, 2009, 114, 4295-4295.	0.6	0
92	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leukemia Research, 2008, 32, 904-912.	0.4	55
93	Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leukemia Research, 2008, 32, 1724-1734.	0.4	12
94	Estimates of Relative Risks for Cancers in a Population after Prolonged Low-Dose-Rate Radiation Exposure: A Follow-up Assessment from 1983 to 2005. Radiation Research, 2008, 170, 143-148.	0.7	47
95	Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Letters, 2008, 268, 314-324.	3.2	187
96	Clinical Characteristics and Treatment Response of Hodgkin's Lymphoma in Taiwan. Journal of the Formosan Medical Association, 2008, 107, 4-12.	0.8	6
97	Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15)—Analysis of 536 Patients. Blood, 2008, 112, 2535-2535.	0.6	1
98	Hierarchical Cluster Analysis of Immunophenotype in AML Patients with NPM1 Gene Mutation Reveals Two Distinct Groups with Different Prognosis Blood, 2008, 112, 1495-1495.	0.6	0
99	Methylation Status of miRNA Let-7a-3 in Acute Myeloid Leukemia. Blood, 2008, 112, 4482-4482.	0.6	0
100	Acquisition and Cure of Autoimmune Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Journal of the Formosan Medical Association, 2007, 106, 779-783.	0.8	3
101	Anaplastic Large Cell Lymphoma in Leukemic Transformation: Successful Treatment by Transplantation. Journal of Clinical Oncology, 2007, 25, 4490-4492.	0.8	2
102	Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma. Cancer Investigation, 2007, 25, 140-147.	0.6	14
103	Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: No impact on early mortality and intracranial hemorrhage. American Journal of Hematology, 2007, 82, 976-980.	2.0	86
104	Epidemiology of multiple myeloma in Taiwan. Cancer, 2007, 110, 896-905.	2.0	92
105	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology, 2007, 139, 405-414.	1.2	122
106	Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein Alpha Is Epigenetically Down-Regulated in Acute Myeloid Leukemia Blood, 2007, 110, 2113-2113.	0.6	2
107	Characterization of Acute Myeloid Leukemia with PTPN11 Mutation - The Mutation Is Closely Associated with NPM1 Mutation but Inversely Related to FLT3/ITD Blood, 2007, 110, 3490-3490.	0.6	2
108	Gene Mutations, Their Interactions and Associations with Immunophenotypes of Leukemia Cells in Patients with Primary Acute Myeloid Leukemia Blood, 2007, 110, 4138-4138.	0.6	0

#	Article	IF	CITATIONS
109	The usefulness of the PlateliaCandidaantigen in a patient with acute lymphocytic leukemia and chronic disseminated candidiasis. Medical Mycology, 2006, 44, 647-650.	0.3	7
110	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. British Journal of Haematology, 2006, 135, 317-323.	1.2	32
111	Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Research, 2006, 66, 3310-3316.	0.4	165
112	Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation Blood, 2006, 108, 561-561.	0.6	6
113	Significance of Marrow Angiogenesis Factors in Patients with Acute Myelogenous Leukemia Blood, 2006, 108, 4424-4424.	0.6	0
114	Prophylactic Use of Moxifloxacin in Patients Receiving Bone Marrow Transplants Was Not Associated with Increased Ciprofloxacin Resistance inEscherichia coli and Enterococci. Clinical Infectious Diseases, 2005, 40, 1862-1864.	2.9	2
115	Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells. Clinical Cancer Research, 2005, 11, 1372-1379.	3.2	202
116	Clinical and Microbiological Characteristics ofRhizobium radiobacterInfections. Clinical Infectious Diseases, 2004, 38, 149-153.	2.9	147
117	Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer, 2004, 100, 366-375.	2.0	185
118	Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy. Annals of Thoracic Surgery, 2004, 78, 267-272.	0.7	42
119	Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. Journal of the Formosan Medical Association, 2004, 103, 526-32.	0.8	34
120	Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. Quality of Life Research, 2003, 12, 503-517.	1.5	29
121	Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Annals of Hematology, 2003, 82, 558-564.	0.8	15
122	SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes and Cancer, 2003, 37, 300-305.	1.5	108
123	Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. British Journal of Haematology, 2002, 117, 835-841.	1.2	73
124	Methylation of the p15 INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. British Journal of Haematology, 2001, 112, 148-154.	1.2	140
125	Transcriptional Regulation of Endothelial Nitric-oxide Synthase by an Interaction between Casein Kinase 2 and Protein Phosphatase 2A. Journal of Biological Chemistry, 1999, 274, 34669-34675.	1.6	50
126	Persistent leucocyte abnormalities in children years after previous long-term low-dose radiation exposure. British Journal of Haematology, 1999, 106, 954-959.	1.2	13

#	Article	IF	CITATIONS
127	High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers. Breast Cancer Research and Treatment, 1998, 49, 237-244.	1.1	2
128	Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. British Journal of Haematology, 1998, 103, 1092-1095.	1.2	120
129	Clonal disease of natural killer large granular lymphocytes in Taiwan. British Journal of Haematology, 1998, 103, 1124-1128.	1.2	14
130	Homozygous Deletion of the p16INK4A Gene Occurs More Frequently in CD2+ Than in CD2â^' T-Cell Acute Lymphoblastic Leukemia. Blood, 1998, 91, 1829-1830.	0.6	3
131	Involvement of Two Sp1 Elements in Basal Endothelial Prostaglandin H Synthase-1 Promoter Activity. Journal of Biological Chemistry, 1997, 272, 6943-6950.	1.6	58
132	Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. British Journal of Haematology, 1997, 97, 621-625.	1.2	75
133	Clinical, haematological and molecular studies in patients with chromosome translocation t(7;11): a study of four Chinese patients in Taiwan. British Journal of Haematology, 1997, 96, 682-687.	1.2	41
134	Transcriptional Induction of Endothelial Nitric Oxide Synthase Type III by Lysophosphatidylcholine. Journal of Biological Chemistry, 1995, 270, 17006-17010.	1.6	104
135	Longâ€term diseaseâ€free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by thirdâ€complementarityâ€determining regionâ€specific probes. British Journal of Haematology, 1995, 89, 914-916.	1.2	10
136	Inactivation of the retinoblastoma gene in acute myelogenous leukaemia. British Journal of Haematology, 1992, 82, 502-507.	1.2	32